Cara Therapeutics reports positive top-line results from a Phase 2a trial of an oral tablet formulation of the company’s peripherally selective kappa opioid agonist, CR845, in patients with osteoarthritis (OA) of the knee or hip.

“These results are an important first step in establishing the applicability of an oral formulation of CR845 in treating chronic pain patients and expand the potential clinical utility of CR845 beyond our lead I.V. CR845 program in acute pain,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “Based on these encouraging findings, we plan to conduct a larger double-blind, placebo-controlled Phase 2b trial in 2016.”